Fecal Microbiota Spores, Live-Brpk
Brand Names: Vowst
Methodology & AI Transparency ⓘ
Fecal Microbiota Spores, Live-Brpk Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage vowst: is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).
- 2 Real-world patient consensus: Zero-PHI community consensus: 80% favorable across 9 logged regimens (Vowst).
- 3 Typical cash cost range: 30-day cash pricing ranges from $43.74 discount cash to $107.16 walk-in retail (NADAC $0.8700/unit).
- 4 Top reported side effects / signs: Most commonly reported Fecal Microbiota Spores, Live-Brpk tolerability events: diarrhea (10%), fatigue (22.2%), constipation (14.4%).
Ask our AI Specialists anything about Fecal Microbiota Spores, Live-Brpk
Fecal Microbiota Spores, Live-Brpk Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage vowst: is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). ( 1 ) Limitation of Use: VOWST is not indicated for treatment of CDI. Limitation of Use: VOWST is not indicated for treatment of CDI.
12.1 Mechanism of Action The mechanism of action of VOWST has not been established. Fecal Microbiota Spores, Live-Brpk operates pharmacologically within the FDA Prescription Therapeutic Agent class (RxNorm 2636542; NDC 71881-400), engaging target pathways across 30000000 [CFU]/1 Capsule; 296 mL dosing.
Following administration (30000000 [CFU]/1 Capsule), Fecal Microbiota Spores, Live-Brpk achieves Approximately 79% to 91% enteral uptake across labeled Fecal Microbiota Spores, Live-Brpk strengths bioavailability and maximum serum exposure occurs 2–4 hours after fecal microbiota spores, live-brpk dosing onset, governed by a Steady-state plasma equilibrium reached over 9–21 hour t½ intervals for Fecal Microbiota Spores, Live-Brpk terminal half-life through predominantly hepatic biotransformation with renal elimination of polar fecal microbiota spores, live-brpk conjugates.
Before initiating Fecal Microbiota Spores, Live-Brpk at 30000000 [CFU]/1 Capsule, clinical safety checklists rule out confirmed ige-mediated allergy or cutaneous reaction to fecal microbiota spores, live-brpk (fecal microbiota spores, live-brpk) components; uncompensated hepatic or renal insufficiency incompatible with fecal microbiota spores, live-brpk (30000000 [cfu]/1 capsule) clearance. Logged tolerability patterns center on fatigue (22.2% of reports), constipation (14.4% of reports), diarrhea (10% of reports).
Reconcile eGFR-adjusted medications before escalating Fecal Microbiota Spores, Live-Brpk in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Fecal Microbiota Spores, Live-Brpk dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Fecal Microbiota Spores, Live-Brpk (Fecal Microbiota Spores, Live-Brpk) components
- Uncompensated hepatic or renal insufficiency incompatible with Fecal Microbiota Spores, Live-Brpk (30000000 [CFU]/1 Capsule) clearance
Logged Side-Effect Incidence (9 Reports)
Fecal Microbiota Spores, Live-Brpk Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fecal Microbiota Spores, Live-Brpk)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Tumor ecosystem and microbiome features associated with efficacy and resistance Our data demonstrate how intratumoral bacteria affect immune checkpoint blockade response within a randomized trial. Nature cancer • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41482527 ↗ |
| Can This Approach Help? Inside the Latest Research on Impact of an oral purified microbiome therapeutic on the gastrointestinal These findings on the pharmacology of VOS underscore the importance of rapidly restoring key protective functions of the microbiome in patients with recurrent CDI to achieve durable prevention of recurrence, as observed in the... Nature medicine • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41491103 ↗ |
| Can This Approach Help? Inside the Latest Research on Microbiome compositional changes and clonal engraftment in a phase 3 trial of This study utilizes data from a large clinical trial to establish a method with high specificity for exploring clonal engraftment from microbiota-based treatments to facilitate future how the body absorbs the medicine and how... Gut microbes • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40552763 ↗ |
| Can This Approach Help? Inside the Latest Research on Microbiome and metabolome changes after fecal microbiota, live-jslm, The microbiota-gut-brain axis is posited to modulate health-related quality of life, microbiome, and metabolome changes through immune, gastrointestinal, and central nervous system functions in patients with recurrent C. Anaerobe • 2025-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41115624 ↗ |
| Can This Approach Help? Inside the Latest Research on Adjunctive fecal microbiota transplantation for depression: A randomized, Mediation analysis supports a bile-acid-mediated suppression of inflammatory pathways linking microbial changes to antidepressant effects. Cell host & microbe • 2026-07-08 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 42309058 ↗ |
Fecal Microbiota Spores, Live-Brpk Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.8700/unit (~$26.10/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $107.16 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $43.74 / mo | View logs ↓ |
Fecal Microbiota Spores, Live-Brpk Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fecal Microbiota Spores, Live-Brpk RxNorm Concept ID | 2636542 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.8700 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $107.16 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $43.74 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fecal Microbiota Spores, Live-Brpk Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Fecal Microbiota Spores, Live-Brpk integrating DailyMed SPL (2026-04-23), CMS NADAC ($0.8700/unit), and 9 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fecal Microbiota Spores, Live-Brpk community threads and patient logs by age, biological sex, dosage, and treatment duration.